Cizzle Biotechnology Holdings PLC (LSE:CIZ) has raised an additional £250,000 through convertible loan notes from investor Frazer Lang to accelerate the rollout of its CIZ1B biomarker test for the early detection of lung cancer. The new capital will help broaden the test’s reach across North America, the UK, and Europe, while also supporting the company’s ongoing collaborations with healthcare partners such as the NHS to improve early cancer screening and diagnosis.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics company focused on developing innovative blood tests for the early detection of cancer. Its flagship product, the CIZ1B biomarker test, offers a non-invasive method to identify lung cancer in its initial stages. The company continues to build strategic partnerships to commercialize its proprietary technology and is listed on the London Stock Exchange.
Leave a Reply